Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Adjuvant cisplatin regimens for locoregionally advanced head and neck squamous cell carcinoma: A meta-analysis.

Amna Gul, Jean-Pierre Obeid, Arslan Inayat et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18121

e18121 Background: The optimal postoperative cisplatin dosing schedule for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) re...

Clinical characteristics and treatment outcomes of hepatosplenic T-cell lymphoma: Mayo Clinic experience.

Syeda A. Mina, Raphael Mwangi, Ayo Samuel Falade et al. Jun 01, 2025 pp. 7075-7075 10.1200/jco.2025.43.16_suppl.7075

7075 Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive peripheral T-cell lymphoma arising primarily from γδ T-cells. It carries a po...

Comparison of mobile mammography versus urban hospital-based breast cancer screening.

Carla Zeballos Torrez, Christine E. Edmonds, Brian S. Englander et al. Jun 01, 2025 pp. 1605-1605 10.1200/jco.2025.43.16_suppl.1605

1605 Background: Breast cancer screening via mobile mammography units (MMU) is used to improve access in medically underserved communities. This study aim...

Transoral robotic surgery (TORS) and de-escalated adjuvant therapy for human papillomavirus-related oropharyngeal carcinoma (HPVOPC): Long-term follow up of the Sinai Robotic Surgery (SIRS) trial (NCT02072148).

Marshall R. Posner, Megan Tang, Joseph Correa et al. Jun 01, 2025 pp. 6089-6089 10.1200/jco.2025.43.16_suppl.6089

6089 Background: De-escalation therapy for HPVOPC remains undefined and controversial. Definitive and postoperative chemoradiation are associated with sig...

Accuracy of MRI in the detection of pathological complete response post neoadjuvant therapy in locally advanced colorectal cancer.

Dr Madhu S.D., Dr Sachin D.K., Narasimhaiah Srinivasaiah et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15670

e15670 Background: Pathological Complete Response (pCR) conventionally denotes the absence of malignant cells in rectal specimens resected from patients w...

Global trends in disability adjusted life years (DALYs) and mortality rates in gastric cancer among elderly (70+ Years) from 1990-2021: A Global Burden of Disease study.

Lay She Ng, Mian Zahid Jan Kakakhel, Husnain Ahmad et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16133

e16133 Background: Although the incidence and mortality of gastric cancer have decreased over the past decades due to the progress in diagnostic methods,...

Clinicopathological and prognostic characteristics of gastric-type endocervical adenocarcinoma: A single-center retrospective study.

Yang Liu, Hui Wang, Xiaolei Lin et al. Jun 01, 2025 pp. 5525-5525 10.1200/jco.2025.43.16_suppl.5525

5525 Background: Gastric-type endocervical adenocarcinoma (G-EAC) is a rare and highly aggressive subtype of cervical cancer. Limited screening methods of...

Long-term follow-up of patterns of melanoma early and late recurrence after adjuvant anti-PD1 therapy.

Christy Jesme, John Marsiglio, Feng Bingjian et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21527

e21527 Background: Despite the promise of immune checkpoint inhibitors (ICI), 25-30% of stage III/IV patients (pts) with (w) resected melanoma develop rel...

Technical performance of the L3 Skeletal Muscle Index in CT.

Hubert Beaumont, Emilie Khayat, Alexandre Thinnes et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24073

e24073 Background: Skeletal muscle, beyond mobility, is now seen as a vital endocrine organ with significant metabolic roles affecting overall health. Ass...

Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel).

Derrick Law Tao, Reham Abdel-Wahab, Ruitao Lin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps9602

TPS9602 Background: For patients with relapsed and/or refractory metastatic melanoma (RRFM), there is a critical need to test novel strategies with improv...

Efficacy and safety of depatuxizumab mafodotin (ABT-414) in EGFR-amplified glioblastoma: A systematic review and Bayesian network meta-analysis.

Sunjida Amin Promi, Ibrahim Khalil, Umme Kulsum et al. Jun 01, 2025 pp. 2060-2060 10.1200/jco.2025.43.16_suppl.2060

2060 Background: Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis, typically resulting in a median survival of 12–15 months. Ep...

Systematic review of BCMA-targeted therapies in relapsed/refractory (R/R) multiple myeloma (MM).

Judith Pérez-Granado, Kamal S. Saini, Carmen Besliu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19528

e19528 Background: MM patients still face unmet medical needs, especially in the R/R setting. Recent breakthroughs in B cell maturation antigen (BCMA)-tar...

Real-world outcomes of nivolumab plus ipilimumab versus immune checkpoint inhibitor and tyrosine kinase inhibitor combinations as first-line treatment for metastatic clear cell renal cell carcinoma.

Faisal Azam, Mubarak Mahdi Almansour, Bassam Mohammed Basulaiman et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16510

e16510 Background: The management of metastatic clear cell renal cell carcinoma (mccRCC) has evolved significantly with the introduction of immune checkpo...

Impact of socioeconomic and demographic factors on treatment-related time intervals in oral cavity cancers: National Cancer Database study.

Shreya Rangarajan, Pranav Dorbala, Mahima Goel et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18122

e18122 Background: Oral cavity squamous cell carcinoma (OCSCC) has high mortality, recurrence, and metastasis, requiring multimodal treatment. Treatment d...

Effect of pre-biopsy steroids on diagnostic yield in diffuse large B-cell lymphoma (DLBCL).

Sathwik Madireddy, Kelly Pan, Sovijja Pou et al. Jun 01, 2025 pp. 7072-7072 10.1200/jco.2025.43.16_suppl.7072

7072 Background: DLBCL is an aggressive lymphoma, and patients (pts) often require urgent steroid administration for symptom relief or organ compromise pr...

Knowledge and barriers to breast and cervical cancer screening in rural Nigerian communities: An ethnographic study.

Emeka Odiaka, Sussan Israel-Isah, Tunde Alabi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23233

e23233 Background: There is a growing need for health researchers, policymakers, and practitioners in resource-limited settings to leverage ethnography fo...

Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study.

Jeeyeon Elizabeth Lee, Won Hwa Kim, Ava Kwong et al. Jun 01, 2025 pp. 1569-1569 10.1200/jco.2025.43.16_suppl.1569

1569 Background: To evaluate the effectiveness of a real-time AI-based computer-aided detection/diagnosis (AI-CAD) system as a diagnostic decision support...

A novel non-invasive machine learning model for predicting tertiary lymphoid structures and treatment response to neoadjuvant therapy in triple-negative breast cancer: A multicenter retrospective study.

Yidan Lin, Yushuai Yu, Qing Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13596

e13596 Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and neoadjuvant therapy (NAT) has become an essenti...

DLBCL-associated PIM1 mutation and its impact on ANXA2 localization and lymphomagenesis.

Yaxiao Lu, Ning Zhang, Ningning Zhang et al. Jun 01, 2025 pp. 7060-7060 10.1200/jco.2025.43.16_suppl.7060

7060 Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and has an overall cure rate of approximately 60...

Levels of immune responses in tertiary lymphoid structures of non-small cell lung cancer (NSCLC) and association with survival.

Jiangping Li Jun 01, 2025 pp. 2627-2627 10.1200/jco.2025.43.16_suppl.2627

2627 Background: Tumor-infiltrating tertiary lymphoid structures (TLSs) are thought to have anti-tumor activity and are believed to indicate a favorable p...

Comparison of intraoperative ex-vivo electrical impedance measurements for oral squamous cell carcinoma.

Jillian Alyse Moran, Sophie Lloyd, Noor Zaghlula et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18100

e18100 Background: Oral squamous cell carcinoma (OSCC) is a prevalent, lethal cancer representing 4.6% of global cancer-related deaths. 60% of oral cancer...

Patterns and clinical significance of high-risk secondary cytogenetic abnormalities at first relapse in multiple myeloma.

Manraj Singh Sra, Linda Baughn, Prashant Kapoor et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19545

e19545 Background: Cytogenetic abnormalities (CA) at diagnosis are important prognostic factors in multiple myeloma (MM), but there is limited information...

Triple-negative breast cancer remodeling of the tissue immune microenvironment by regulation of embryonic-derived tissue-resident macrophage polarization through the IRF7/CH25H/25HC pathway.

Yalong Yang, Xinhong Wu, Hongmei Zheng Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14557

e14557 Background: The immune microenvironment of breast cancer is richly infiltrated with macrophages, yet modulation targeting macrophage polarization h...

Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates: A TriNetX real-world evidence study.

Zunairah Shah, Safa Saadat Afridi, Mustafa Ali Samejo et al. Jun 01, 2025 pp. 1036-1036 10.1200/jco.2025.43.16_suppl.1036

1036 Background: HER2-positive breast cancer (HER2+ BC) is an aggressive BC subtype driven by overexpression of the human epidermal growth factor receptor...

Safety and efficacy of chimeric antigen receptor (CAR)–T cell therapy (BRG01) targeting the Epstein-Barr virus (EBV) envelope protein in EBV+ lymphoproliferative disease patients.

Xinfeng Chen, Guohui Qin, Dan Wang et al. Jun 01, 2025 pp. 7079-7079 10.1200/jco.2025.43.16_suppl.7079

7079 Background: Epstein-Barr virus (EBV) is a type I carcinogen which has infected more than 95% of population. EBV infection is closely associated with...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page